Jaka jest cena za ABIONYX Pharma S.A. (ABNX)

Cena za ABIONYX Pharma S.A. (ABNX) wynosi $2.32

Jaka jest kapitalizacja rynkowa dla ABIONYX Pharma S.A. (ABNX)

Kapitalizacja rynkowa dla ABIONYX Pharma S.A. (ABNX) wynosi $98.03M

Przychody ABIONYX Pharma S.A. (ABNX)

ABIONYX Pharma SA is a biotechnology company dedicated to the identification and advancement of therapies for conditions affecting the kidneys and eyes. The firm's pipeline includes CER-001, an innovative negatively-charged lipoprotein particle. This compound is designed to mimic the structural and functional attributes of pre-beta HDL, utilizing human recombinant apoA-I (a natural high-density lipoprotein protein) along with natural phospholipids like sphingomyelin and dipalmitoylphosphatidylglycerol. CER-001 is currently under development for patients recovering from acute coronary syndrome and those with familial primary hypoalphalipoproteinemia. Another key candidate, CER-002, is a specific agonist for peroxisome proliferator-activated receptor delta, targeting cardiovascular and metabolic diseases. Additionally, CER-209 is being developed as a potential treatment for metabolic liver diseases, atherosclerosis, and non-alcoholic steatohepatitis (NASH). ABIONYX maintains strategic partnerships with GTP Biologics and VBI Therapeutics Group for the bioproduction of its bio-HDL in France. Established in 2005, the company operated as Cerenis Therapeutics Holding SA before its rebranding to ABIONYX Pharma SA in August 2019. Its operations are headquartered in Balma, France.

Rok	Przychody	Zmień
Za mało danych dla podanych dat.

Rok

Przychody

Zmień

Za mało danych dla podanych dat.

Firma	Przychody	Różnica w przychodach	Kraj
Vertex Pharmaceuticals Incorporated VRTX.US	$12.62B	-	US
Argenx SE ARGX.US	$6.02B	-	NL
Moderna, Inc. MRNA.US	$2.23B	-	US
CSL Limited CSL.AX	$15.74B	-	AU
Lonza Group AG LONN.SW	-	-	CH

Firma

Przychody

Różnica w przychodach

Kraj